The first injection of a new type of drug to treat diabetes, cancer and immunology therapeutic areas has been launched in the United States after five years of experience in Europe, Canada and Canada, according to the company's chief medical officer, Biocon.
Source: prnewswire.comPublished on 2023-07-03
Related news
- Lamb Weston Issues FY22 ESG Report | MarketScreener
- Is your firm ready for sustainable financing ?
- FCC Forecast : Canadian Farm Income Expected To Increase In 2 ...
- Sustainable Investing Works
- ESAs deliver adjusted SFDR requirements , say careful balance struck | News
- The Supreme Court has curtailed EPA power to regulate carbon pollution – and sent a warning to other regulators
- Will SEC Become The Securities And Environment Commission ? - Corporate / Commercial Law
- Ten - fold increase in carbon offset cost predicted
- Aflac Incorporated Publishes Second - Year Sustainability Bond Report
- KAVALAN and Epson PVC - Free Partnership Set to Inspire at Sustainability - Focused FESPA
- UK Sustainability Disclosure Requirements : FCA Announces Delay | Proskauer Rose LLP
- The three European Supervisory Authorities publish Final Report and draft RTS on disclosures under SFDR
- Supreme Court EPA Decision Sends Warning to Regulators
- Bríd Smith : Expansion of data centres is not going to help our serious energy woes
- OEMs Avoid Greenwashing With Supply - Chain Scrutiny